SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

Home・Listă Acțiuni・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

59.4 -0.17

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

58.85

Maxim

60.35

Indicatori cheie
By Trading Economics
Venit	-33M 9.5M
Vânzări	-66M 152M
P/E Medie Sector	26.292 51.415
EPS	0.834
Marjă de profit	6.216
Angajați	1,950
EBITDA	-45M 18M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+22.97% upside

Dividende
By Dow Jones
Următoarele câștiguri	23 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-887M 3.2B
Deschiderea anterioară	59.57
Închiderea anterioară	59.4

Sentimentul știrilor

By Acuity

50%

171 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

51.1 / N/A Suport & Rezistență

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Achiziții, Fuziuni, Preluări

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Câștiguri

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs

15 mai 2026, 00:00 UTC

Câștiguri

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mai 2026, 23:57 UTC

Achiziții, Fuziuni, Preluări

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Achiziții, Fuziuni, Preluări

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q Rev $4.97B >NU

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

22.97% sus

Prognoză pe 12 luni

Medie 73.6 EUR 22.97%

Maxim 83 EUR

Minim 64.2 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Laboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

171 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.